Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...

The global Paroxysmal Supraventricular Tachycardia (PSVT) market is set for significant growth, driven by advancements in diagnostics and treatment, and rising cardiovascular awareness. Key factors ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

HealthDay News — An experimental nasal spray, etripamil, may benefit patients with paroxysmal supraventricular tachycardia (PSVT), according to a study presented at the annual meeting of the Heart ...

Self-treatment of acute paroxysmal supraventricular tachycardia (SVT) with a nasal spray containing a short-acting calcium-channel blocker is likely to be possible with a high rate of conversion to ...

Supported by a grant (HE 12373) from the Public Health Service and a grant from the San Diego County Heart Association. We are indebted to Dr. David B. Carmichael, who referred the patient for ...